Tested Applications
| Positive IP detected in | K-562 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Immunoprecipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
26207-1-AP targets HDAC7 in WB, IHC, IP, CoIP, ELISA applications and shows reactivity with human, rat samples.
| Tested Reactivity | human, rat |
| Cited Reactivity | human, mouse |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag24396 Product name: Recombinant human HDAC7 protein Source: e coli.-derived, PET30a Tag: 6*His Domain: 447-530 aa of BC006453 Sequence: EEGWKQKPNLNAIRSLEAVIRVHSKYWGCMQRLASCPDSWVPRVPGADKEEVEAVTALASLSVGILAEDRPSEQLVEEEEPMNL Predict reactive species |
| Full Name | histone deacetylase 7 |
| Calculated Molecular Weight | 103 kDa |
| Observed Molecular Weight | 102 kDa |
| GenBank Accession Number | BC006453 |
| Gene Symbol | HDAC7 |
| Gene ID (NCBI) | 51564 |
| RRID | AB_2880426 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q8WUI4 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Protocols
| Product Specific Protocols | |
|---|---|
| IP protocol for HDAC7 antibody 26207-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The HDAC7 Polyclonal antibody (Cat# 26207-1-AP) has 8 citations. These appear in journals including J Exp Clin Cancer Res, Cell Death Dis, Int J Biol Sci, Hepatol Commun, Commun Biol, Am J Physiol Cell Physiol, and Cell Biol Int. The research spans oncology (NSCLC, cholangiocarcinoma, ovarian cancer, hepatocellular carcinoma, lung adenocarcinoma, glioblastoma), EMT, HDAC7 signaling, protein stability regulation, and endothelial cell biology, with applications primarily in WB, IHC, CoIP, and IP.
| Species | Application | Title |
|---|---|---|
J Exp Clin Cancer Res HDAC7 promotes NSCLC proliferation and metastasis via stabilization by deubiquitinase USP10 and activation of β-catenin-FGF18 pathway.
| ||
Cell Death Dis AZGP1 activation by lenvatinib suppresses intrahepatic cholangiocarcinoma epithelial-mesenchymal transition through the TGF-β1/Smad3 pathway | ||
Int J Biol Sci Discovery of a novel HDACi structure that inhibits the proliferation of ovarian cancer cells in vivo and in vitro. | ||
Int J Biol Sci DNMT3a promotes LUAD cell proliferation and metastasis by activating the HDAC7 signalling pathway
| ||
Hepatol Commun ARID1A deficiency promotes malignant proliferation of hepatocellular carcinoma by activating HDAC7/ENO1 signaling pathway. | ||
Commun Biol Interplay between acetylation and ubiquitination controls PSAT1 protein stability in lung adenocarcinoma |



